Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 252

  • The following term was ignored: -
  • See the search details.
1.

[Cervical cancer: particularities in HIV patients].

Grellier N, Quéro L.

Bull Cancer. 2014 Nov;101(11):1040-7. doi: 10.1684/bdc.2014.2034. Review. French.

PMID:
25418597
2.

Study points to value of HPV screening for cervical cancer: test may be viable alternative to Pap test.

Printz C.

Cancer. 2014 Dec 1;120(23):3589-90. doi: 10.1002/cncr.29126. No abstract available.

PMID:
25410486
3.

Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial.

Haguenoer K, Sengchanh S, Gaudy-Graffin C, Boyard J, Fontenay R, Marret H, Goudeau A, Pigneaux de Laroche N, Rusch E, Giraudeau B.

Br J Cancer. 2014 Nov 25;111(11):2187-96. doi: 10.1038/bjc.2014.510. Epub 2014 Sep 23.

PMID:
25247320
4.

[Uterine cervical cancer screening in kitakyushu city: present and future].

Matsuura Y, Oka H, Yamagata K, Kikuchi J, Inoue I, Ohkubo N, Toki N, Kawagoe T, Hachisuga T, Kashimura M.

J UOEH. 2014 Sep 1;36(3):205-15. Japanese.

5.

A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology.

Kisser A, Zechmeister-Koss I.

BJOG. 2015 Jan;122(1):64-70. doi: 10.1111/1471-0528.13076. Epub 2014 Sep 11. Review.

PMID:
25208923
6.

Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.

Gage JC, Katki HA, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Castle PE, Kinney WK.

Int J Cancer. 2015 Apr 1;136(7):1665-71. doi: 10.1002/ijc.29143. Epub 2014 Sep 2.

PMID:
25136967
7.

A survey of Jordanian obstetricians and gynecologists' knowledge and attitudes toward human papillomavirus infection and vaccination.

Lataifeh I, Obeidat N, Al-Mehaisen L, Khriesat W, Tadros R, Khader Y, Al-Sukhun S.

Eur J Gynaecol Oncol. 2014;35(4):429-32.

PMID:
25118486
8.

Protecting the underscreened women in developed countries: the value of HPV test.

Ibáñez R, Autonell J, Sardà M, Crespo N, Pique P, Pascual A, Martí C, Fibla M, Gutiérrez C, Lloveras B, Moreno-Crespi J, Torrent A, Baixeras N, Alejo M, Bosch FX, de Sanjosé S.

BMC Cancer. 2014 Aug 8;14:574. doi: 10.1186/1471-2407-14-574.

9.

The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.

Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Behrens C, Sharma A, Zhao FH, Cuzick J, Yang ZH, Kinney WK.

Cancer Cytopathol. 2014 Nov;122(11):842-50. doi: 10.1002/cncy.21463. Epub 2014 Jul 9.

PMID:
25045058
10.

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Jul 18;106(8). pii: dju153. doi: 10.1093/jnci/dju153. Print 2014 Aug.

PMID:
25038467
11.

HPV vaccination: effects on cervical screening.

Kothari A.

Nurs Times. 2014 Jun 11-17;110(24):19-21.

PMID:
25007499
12.

Pre-vaccination prevalence of infections with 25 non-high-risk human papillomavirus types among 1,000 Slovenian women in cervical cancer screening.

Učakar V, Poljak M, Oštrbenk A, Klavs I.

J Med Virol. 2014 Oct;86(10):1772-9. doi: 10.1002/jmv.23997. Epub 2014 Jun 30.

PMID:
24978445
13.

Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study.

Agorastos T, Chatzistamatiou K, Zafrakas M, Siamanta V, Katsamagkas T, Constantinidis TC, Lampropoulos AF; LYSISTRATA study group.

Eur J Cancer Prev. 2014 Sep;23(5):425-31. doi: 10.1097/CEJ.0000000000000060.

PMID:
24977385
14.

Concordance in cervical HPV detection between hybrid capture 2 and HPV GenoArray tests.

Zhang L, Lin Y, Li JK.

Asian Pac J Cancer Prev. 2014;15(11):4465-6.

15.

"If you can't treat HPV, why test for it?" Women's attitudes to the changing face of cervical cancer prevention: a focus group study.

McRae J, Martin C, O'Leary J, Sharp L; Irish Cervical Screening Research Consortium (CERVIVA).

BMC Womens Health. 2014 May 6;14:64. doi: 10.1186/1472-6874-14-64.

16.

Development and validation of a new HPV genotyping assay based on next-generation sequencing.

Yi X, Zou J, Xu J, Liu T, Liu T, Hua S, Xi F, Nie X, Ye L, Luo Y, Xu L, Du H, Wu R, Yang L, Liu R, Yang B, Wang J, Belinson JL.

Am J Clin Pathol. 2014 Jun;141(6):796-804. doi: 10.1309/AJCP9P2KJSXEKCJB.

PMID:
24838323
17.

Differences in the level of knowledge on cervical cancer among health care students, midwives and patients in Serbia.

Antic LG, Djikanovic BS, Antic DZ, Aleksopulos HG, Trajkovic GZ.

Asian Pac J Cancer Prev. 2014;15(7):3011-5.

18.

Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies.

Saraiya M, Benard VB, Greek AA, Steinau M, Patel S, Massad LS, Sawaya GF, Unger ER.

Am J Obstet Gynecol. 2014 Oct;211(4):354.e1-6. doi: 10.1016/j.ajog.2014.05.001. Epub 2014 May 6.

19.

[Liquid-based cervical cytology ThinPrep screening in Hungary].

Bak M, Séberné Éll M, Bóka M, Veleczki Z, Nyári T, Pete I, Szentirmay Z.

Orv Hetil. 2014 May 4;155(18):708-14. doi: 10.1556/OH.2014.29875. Hungarian.

PMID:
24776385
20.

Performance of self-sampled HPV test in comparison with liquid based cytology.

Igidbashian S, Boveri S, Radice D, Casadio C, Spolti N, Sandri MT, Sideri M.

Eur J Obstet Gynecol Reprod Biol. 2014 Jun;177:72-6. doi: 10.1016/j.ejogrb.2014.03.028. Epub 2014 Apr 8.

PMID:
24768230
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk